Because dual targeting is thought to enhance biological efficacy, limit escape mechanisms, and increase target selectivity via a strong avidity effect mediated by concurrent binding, several iMab-based bispecific antibodies were created by genetically fusing iMab with broadly HIV-neutralizing antibodies (bNAbs), including anti-gp120 antibodies PG9 or PG16 (Pace et al., 2013b), m36.4 (Sun et al., 2014), CAP256 (Moshoette et al., 2019), and anti-gp41 antibody 10E8 (Huang et al., 2016), which did show greatly improved activities to inhibit HIV-1 infection and overcome the resistance problem. This evidence concerns the gene ITIH4 and HIV-1 infection.